Erasca, Inc.

What they do

Erasca discovers, develops, and plans to commercialize therapies for patients with RAS/MAPK pathway-driven cancers, which the company says account for more than five million new cancer diagnoses globally each year. Its pipeline includes two clinical-stage programs: ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, plus ERAS-12, a discovery-stage EGFR D2/D3 biparatopic antibody. The company in-licensed its RAS-targeting franchise in May 2024 and pursues modality-agnostic programs under three strategies: targeting upstream/downstream MAPK nodes, targeting RAS directly, and targeting escape routes.

Revenue drivers

• ERAS-0015 (pan-RAS molecular glue) — Lead clinical-stage program; no product revenue. The company reported updated AURORAS-1 Phase 1 data in KRAS G12X PDAC and is advancing the program toward three potentially registration-enabling trials in pancreatic and lung cancers.
• ERAS-4001 (pan-KRAS inhibitor) — Second clinical-stage program; no product revenue. Phase 1 preliminary monotherapy data are expected in the second half of 2026.
• ERAS-12 (EGFR D2/D3 biparatopic antibody) — Discovery-stage program with a lead candidate identified; no revenue and no clinical data disclosed.
• Financing proceeds — The company funds operations through equity offerings, not product sales, including a July 2026 upsized public offering of approximately $632.5 million in gross proceeds and a January 2026 offering of approximately $258.8 million.

Recent performance

Erasca has no product revenue and reported net losses each year from 2021 through 2025: $-122.8M, $-242.8M, $-125.0M, $-161.7M, and $-124.5M, respectively. Diluted EPS improved from $-1.85 in 2021 to $-0.44 in 2025. Operating cash flow was negative every year, including $-95.5M in 2025. As of June 30, 2026, total assets were $435.1M, total liabilities $73.2M, shareholder equity $361.9M, and cash and equivalents $42.5M; the company separately reported cash, cash equivalents, and marketable securities of $384 million as of June 30, 2026. No dividends have been paid.

Strategy

Erasca states it intends to comprehensively shut down the RAS/MAPK pathway by combining agents that target upstream/downstream nodes, RAS directly, and escape routes. It is prioritizing ERAS-0015 across high-value KRAS-mutant indications, including potentially registration-enabling development in pancreatic and lung cancers, and is also studying ERAS-0015 in combination with the approved dose of panitumumab in colorectal cancer. The company in-licensed its RAS-targeting franchise in May 2024 and describes its approach as modality-agnostic, including small and large molecule therapeutics. Recent financing is intended to accelerate ERAS-0015 and maintain momentum across the broader pipeline.

Risks

• No approved products or revenue — Erasca is clinical-stage with no product revenue and has reported net losses every year from 2021 through 2025, including $-124.5M in 2025.
• Early clinical data — The ERAS-0015 efficacy figures cited, such as 57% uORR 8wk in 2L+ KRAS G12X PDAC, are preliminary from an ongoing Phase 1 trial and may not be confirmed or replicated.
• Cash consumption and financing need — Operating cash flow was negative $95.5M in 2025, and cash and equivalents were $42.5M at June 30, 2026, making the company dependent on equity financings such as the July 2026 offering.
• Dependence on in-licensed RAS franchise — The RAS-targeting franchise, including ERAS-0015 and ERAS-4001, was in-licensed in May 2024, so development and commercialization depend on rights retained under that license.

Outlook

Management says the July 2026 financing should position Erasca to accelerate ERAS-0015 toward three potentially registration-enabling trials while maintaining momentum across the pipeline. The company expects additional ERAS-0015 monotherapy and combination data in the first half of 2027, and ERAS-4001 Phase 1 preliminary monotherapy data in the second half of 2026. It also plans continued dose escalation and backfill enrollment for the ERAS-0015 plus panitumumab combination in colorectal cancer.